✦ LIBER ✦

European guidelines for the use of anti-tumour necrosis factor agents in inflammatory bowel disease

✍ Scribed by Wolfgang Kruis

Publisher: Springer
Year: 2001
Tongue: English
Weight: 13 KB
Volume: 16
Category: Article
ISSN: 0179-1958
DOI: 10.1007/s003840100294

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of anti-tumour necrosis factor agent

Use of anti-tumour necrosis factor agents in inflammatory bowel disease

✍ S. Schreiber; M. Campieri; J.F. Colombel; S.J.H. van Deventer; B. Feagan; R. Fed 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 54 KB

Differences in the incidence of flares o

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents

✍ Braun, J. ;Baraliakos, X. ;Listing, J. ;Davis, J. ;van der Heijde, D. ;Haibel, H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti–tumor necrosis factor (anti‐TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative co

Effect of the anti-tumor necrosis factor

Effect of the anti-tumor necrosis factor-α antibody infliximab on the ex vivo mucosal matrix metalloproteinase–proteolytic phenotype in inflammatory bowel disease

✍ Martin J. Meijer; Marij A.C. Mieremet-Ooms; Wim van Duijn; Annie M. van der Zon; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 478 KB

## Background: Previous studies have shown an upregulation of matrix metalloproteinases (mmps) in intestinal tissue of patients with inflammatory bowel disease (ibd) and significant clinical improvement after administration of the anti-tnf-a antibody infliximab. the aims of our study were to determ

The impact of anti-tumour necrosis facto

The impact of anti-tumour necrosis factor therapy for rheumatoid arthritis on the use of other drugs and hospital resources in a pragmatic setting

✍ R. S. Sandhu; G. J. Treharne; K. M. J. Douglas; K Cassim; A. Saratzis; H. Piper; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB

The Disease Activity Score is not suitab

The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti–tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes

✍ Frederick Wolfe; Kaleb Michaud; Theodore Pincus; Daniel Furst; Edward Keystone 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

## Abstract ## Objective The Disease Activity Score (DAS) is widely used in clinical trials. A DAS of 5.1 defines the level of severe rheumatoid arthritis (RA) and is the criterion for the initiation of anti–tumor necrosis factor therapy in the UK and The Netherlands. In North America, similar rul